HSP27 diagnostic utility in the fine needle aspirate of breast. Correlation with progesterone and estrogen receptors

Neoplasma

Volumn 56, Issue 4, 2009, Pages 357-360

  Mlynarczyk Liszka, J ^a   Maksymiuk, B ^a   Ponikiewska, D ^a   Krzyzowska Gruca, S ^a   Lange, D ^a   Krawczyk, Z ^a   Malusecka, E ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast cancer; Cytology; Fine needle aspiration; HSP27

Indexed keywords

ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; PROGESTERONE RECEPTOR; HSPB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; SMEAR; BREAST; BREAST TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PRECANCER; PREDICTION AND FORECASTING;

BIOPSY, FINE-NEEDLE; BREAST; BREAST NEOPLASMS; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 68149094477     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_04_357     Document Type: Article

References (32)

1. Robinson IA, Blackham RB. Is there a better way to assess performance in breast cytology? Cytopathology 2001; 12: 227-234. doi:10.1046/j.1365-2303.2001. 00330.x
2. Singh N, Wells C A. Assessment of accuracy in breast cytology. Cytopathology 2001; 12: 211-218. doi:10.1046/j.1365-2303.2001.00344.x
3. Niezabitowski A. The usefulness of morphological methods in prognosis and treatment of breast carcinoma. Pat.Pol 1995; 46: 3-10.
4. Deb RA, Matthews P, Elston CW et al. An audit of "equivocal" (C3) and "suspicious" (C4) categories in fine needle aspiration cytology of the breast. Cytopathology 2001; 12: 219-226. doi:10.1046/j.1365- 2303.2001.00332.x
5. Kanhoush R, Jorda M, Gomez-Fernandez C et al. ,Atypical' and ,suspicious' diagnoses in breast aspiration cytology. Cancer 2004; 102: 164-167. doi:10.1002/cncr.20283
6. Kijanienko J, Zajdela A, Lussier Ch et al. Critical clinicopathologic analysis of 23 cases of fine needle breast sampling initially recorded as false-positive. Cancer Cytopathology 2001; 93: 132-139.
7. Masood S. Prognostic/predictive factors in breast cancer. Clin Lab Med 2005; 4: 809-825. doi:10.1016/j.cll.2005.08.012
8. Pusztai L, Ayers M, Stec J et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003; 7: 2406-2415.
9. Gong Y, Yan K, Lin F et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007; 3: 203-211. doi:10.1016/S1470-2045(07)70042-6
10. Sneige N. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. Diagn Cytopathol 2004; 3: 158-165 doi:10.1002/dc.20005
11. Bozzetti C, Nizzoli R, Naldi N et al. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Cancer 1999; 87: 224-230. doi:10.1002/(SICI)1097-0142(19990825)87: 4<224::AID- -CNCR10>3.0.CO;2-5
12. Ball HM, Hupp TR, Ziyaie D et al. Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring. Br J Cancer. 2001; 85: 1102-1105. doi:10.1054/bjoc.2001.2064
13. Park K, Han S, Kim HY et al. Cytologic evaluation of cyclin D1 expression in primary breast carcinoma. Cancer 2001; 93: 211-215. doi:10.1002/cncr.9031
14. Ciocca DR, Vargas-Roig LM Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcel Biol 2002; 28: 205-218.
15. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones Summer 2005; 10: 86-103. doi:10.1379/CSC-99r.1
16. Wong HR, Wispe JR. The stress response and the lung. Am J Physiol 1997; 273: L1-9.
17. Polla BS, Bachelet M, Elia G, Santoro MG. Stress proteins in inflammation. Ann N Y Acad Sci. 1998; 851: 75-85. doi: 10.1111/j.1749-6632.1998. tb08979.x
18. Ciocca DR, Oesterreich S, Chamness GC et al. Biological and clinical implications of heat shock protein 27000 (Hsp27): a Review. J Natl Cancer Inst 1993; 85: 1558-1570 doi:10.1093/jnci/85.19.1558
19. Garrido C, Brunet M, Didelot C et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 22: 2592-2601.
20. Arrigo AP Hsp27: novel regulator of intracellular redox state. IUBMB Life . 2001; 6: 303-337. doi:10.1080/ 152165401317291156
21. O'Neill PA, Shaaban AM, West CR et al. Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer 2004; 90: 182-188. doi:10.1038/sj.bjc.6601449
22. Keeling J, McKee GT. Heat shock protein (HSP)27: a further refinement in the diagnosis of suspicious fine needle aspirates of breast. Cytopathology. 1999; 10: 40-49 doi:10.1046/j.1365- 2303.1999.00140.x
23. Stahlschmidt J, Liston J, Aslam MM et al. Fine needle aspiration cytology of adenoid cystic carcinoma of the breast. Cytopathology 2001; 12: 265-269. doi:10.1046/j.1365-2303.2001.0323b. x
24. Moyes C, Dunne B. Predictive power of cytomorphological features in equivocal (C3, C4) breast FNAC. Cytopathology 2004; 6: 305-310. doi:10.1111/j.1365-2303.2004.00157.x
25. Thor A, Benz C, Moore D et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991; 83: 170-178. doi:10.1093/jnci/83.3.170
26. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993; 3: 239-248. doi:10.1111/j.1365-2559.1993.tb01196.x
27. Love S, King RJ A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer . 1994; 4: 743-748
28. Oesterreich S, Hilsenbeck SG, Ciocca DR et al. The small heat shock protein HSP27 is not independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 1996; 2: 1199-1206.
29. Schneider J, Pollán M, Ruibal A et al. Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer.Tumour Biol. 1999; 20: 319-330 doi:10.1159/000030096
30. Cardoso F, Di Leo A, Larsimont D, Gancberg D et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.Ann Oncol. 2001; 12: 615-620 doi:10.1023/A:1011182524684
31. Ioachim E, Tsanou E, Briasoulis E et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast. 2003; 2: 111-119. doi:10.1016/S0960-9776(02)00290-4
32. Thanner F, Sutterlin MW, Kapp M et al. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005; 3A: 1649-1653.